Talk:Roivant Sciences
| This is the talk page for discussing improvements to the Roivant Sciences article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Archives: 1Auto-archiving period: 152 days  |
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to multiple WikiProjects. | |||||||||||||||||
| ||||||||||||||||||
 | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
Removing the word "reportedly"
edit | This edit request by an editor with a conflict of interest has now been answered. |
Since the deal between Sumitomo Dainippon and Roivant closed on December 30, 2019, I am requesting that the word "reportedly" be removed from the last sentence in the Subsidiaries section where it says "In October 2019, Roivant agreed to sell five of its subsidiaries, Myovant, Urovant, Enzyvant, Altavant and Spirovant — in addition to a greater than 10% share in itself — to Sumitomo Dainippon Pharma, reportedly for US$3 billion dollars." Coverage of the deal can be found here and here and here. Thank you for your consideration, FinalFrontier.003 (talk) 09:58, 5 January 2020 (UTC)
Done Spintendo 16:03, 5 January 2020 (UTC)
Readability and Promotional language
editIt's hard to even tell what this company does with this language, full of jargon and overly promotional language. Does anyone have any info on what pharmaceuticals they sell? This currently reads like an investor report. Marleeashton (talk) 09:16, 26 August 2023 (UTC)